March 2, 2016


inca_logo high res

The International Neuroendocrine Cancer Alliance (INCA)
Appoints First Executive Director, Teodora Kolarova



Ron Hollander, President of the International Neuroendocrine Cancer Alliance (INCA) and Executive Director of the NET Research Foundation (USA), is pleased to announce the appointment of Teodora Kolarova of Bulgaria as INCA’s first Executive Director. Ms. Kolarova was INCA’s President in 2014-2015 and will serve as Executive Director under a contract with her public relations and strategic consultancy company PR Net, based in Sofia, Bulgaria.


“Teodora has proven to be passionate about INCA’s ambition to increase its impact as the global voice for Neuroendocrine Cancer patients, and she is very familiar with the international scene, INCA’s key stakeholders, and its members. The entire INCA membership is delighted with her appointment and excited to work with Teodora and organizations around the globe to advance the cause of ensuring the best information, treatments and research are available to neuroendocrine tumor (NET) patients worldwide,” commented Mr. Hollander.


Coming from a background of strategic communications, Ms. Kolarova has over 17 years of professional experience in public relations, strategic consulting, and project management. In recent years she has been primarily involved in cancer patient advocacy and healthcare awareness raising. Over the last 5 years, Ms. Kolarova’s commitment to promoting cancer awareness and advocacy has focused on neuroendocrine cancers.  Ms. Kolarova was elected a Board Member and Chair of the INCA Communications Committee in 2012.

“While serving INCA has always been an honor for me, I am humbled by the trust INCA members have bestowed on me. It is definitely inspiring and rewarding to be given the chance to facilitate and advance such a global effort. I very much look forward to working with the committed INCA team to help the organization increase the power and influence of the NET patient’s voice,” said Ms. Kolarova, about her new role.


A key focus of INCA, established initially as an informal alliance in 2010 at a meeting in Berlin, Germany, is to raise awareness of neuroendocrine cancer in the healthcare community and throughout the general public. There are currently 18 member patient groups and advocacy organizations from Asia Pacific, Australia, Europe, and North America (listing attached).

Encouraging early diagnosis by working collaboratively with the healthcare community and the public, the Alliance also recognizes universal access to high-quality multidisciplinary care and the dissemination of accurate and user-friendly information about neuroendocrine cancer as its top priorities. A third critical strategic pillar for the Alliance is advancing research on NETs to develop better treatments and cures for all forms of neuroendocrine cancer.


INCA also serves as a global platform to support existing and new patient-focused neuroendocrine groups and advocacy organizations from around the world. By maximizing the resources of its current members and actively reaching out to new ones, INCA encourages sharing best practices and experience, which is crucial in the context of rare cancers.

The current INCA Board members and Officers are:

  • President: Ron Hollander, Executive Director, NET Research Foundation, USA
  • Treasurer: Allen Wilson, President, Pheo Para Troopers, USA
  • Secretary: Yoshiyuki Majima, General Manager, Pancreatic Cancer Action Network, Japan
  • Board Member: Tore Aasbu, Chief Executive Officer, CarciNor, Norway
  • Board Member: Siobhan Conroy, Chief Executive Officer, The Unicorn Foundation, New Zealand
  • Board Member: Simone Leyden, Chief Executive Officer, The Unicorn Foundation, Australia


INCA is a 501c3 nonprofit organization, EIN 46-2961023, headquartered in the United States.


More on INCA at and


Download our press release in .pdf   here ………